Investing.com -- Boston Scientific Corporation reported first-quarter earnings and revenue that surpassed analyst expectations, driving shares up 3.2% in early trading Wednesday.
The medical device maker posted adjusted earnings per share of $0.75 for Q1 2025, beating the consensus estimate of $0.67. Revenue came in at $4.66 billion, topping expectations of $4.57 billion and representing a 20.9% increase YoY.
Boston Scientific (NYSE:BSX) saw robust growth across its business segments. Cardiovascular sales jumped 26.2% YoY to $3.09 billion, while MedSurg revenue rose 11.7% to $1.58 billion.
"We delivered an exceptional quarter to start the year, reflecting the effectiveness of our highly engaged global team and the strength of our product portfolio," said Mike Mahoney, chairman and CEO of Boston Scientific.
The company raised its full-year 2025 adjusted EPS guidance to a range of $2.87 to $2.94 from $2.80-$2.87, also above the analyst consensus of $2.86. It expects organic revenue growth of 12% to 14% for the year.
For Q2 2025, Boston Scientific projects organic revenue growth of 13% to 15% and adjusted EPS between $0.71 and $0.73.
"We delivered an exceptional quarter to start the year, reflecting the effectiveness of our highly engaged global team and the strength of our product portfolio," said Mike Mahoney, chairman and chief executive officer of Boston Scientific. "We remain well-positioned for the future as we continue to focus on meaningful innovation, clinical science and the execution of our category leadership strategy to drive differentiated growth and performance for the long-term."
This content was originally published on Investing.com
